Skip to main content
BDX logo

Becton Dickinson & Company

Exchange: NYSESector: HealthcareIndustry: Medical Instruments & Supplies

Becton Dickinson and Co, formerly Becton Dickinson & Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company' s operations consist of three business segments: BD Medical, BD Diagnostics and BD Biosciences. On February 9, 2012, the Company acquired a 100% interest in KIESTRA Lab Automation BV. On August 24, 2012, the Company acquired a 100% interest in Sirigen Group Limited. On October 31, 2012, the Company sold its BD Biosciences -Discovery Labware unit. In December 2012, the Company acquired Safety Syringes, Inc. Effective March 12, 2013, the Company acquired Cato Software Solutions GmbH.

Did you know?

Profit margin stands at 8.0%.

Current Price

$154.51

-1.17%

GoodMoat Value

$146.37

5.3% overvalued
Profile
Valuation (TTM)
Market Cap$44.10B
P/E25.10
EV$63.09B
P/B1.74
Shares Out285.42M
P/Sales2.01
Revenue$21.92B
EV/EBITDA12.40

Becton Dickinson & Company (BDX) Financial Statements

GoodMoat Analysis

Based on data as of March 26, 2026

Becton Dickinson exhibits a mixed financial profile for a value investor. While it generates a solid free cash flow yield and maintains a reasonable debt level, its growth is minimal and key profitability metrics like ROE are below typical quality thresholds.

Read full analysis
The financial quality of Becton Dickinson presents a nuanced picture. On the positive side, the company demonstrates a strong free cash flow yield of 5.9%, which, if the FCF margin is above 10-15%, would meet the framework's 'Strong' criterion for FCF generation. The balance sheet appears manageable with a Debt/Equity ratio of 0.76, which is below the concerning threshold of 1.0x Debt/EBITDA mentioned in the framework, indicating a neutral-to-strong position. However, several key quality indicators are unfavourable. Revenue growth is anemic at 1.6% YoY, far below the double-digit, sustainable growth sought for a 'Strong' rating. Profitability metrics are weak: an ROE of 6.9% is significantly below the 15-20% high-return threshold, and an operating margin of 11.8% suggests limited operating leverage. The minimal revenue growth also fails the framework's growth assessment, as it shows no acceleration or trajectory above 20%. For a value investor, this points to a stable but stagnant cash-generating business with low returns on capital, rather than a high-quality compounder. The financial health is adequate but lacks the dynamic growth and high profitability that typically define a superior investment candidate under this framework. Analysis based on data as of 2024-05-15.

BDX Financial Data

EBITDA$5.05B
Revenue (TTM)$21.92B
Gross Profit (TTM)$10.10B
Gross Margin
Operating Margin11.80%
ROE6.92%
ROA3.18%
Debt/Equity0.76
Current Ratio1.11
FCF$2.67B
FCF Yield6.05%
Piotroski F-Score
Rev/Share (TTM)$76.81
50-Day MA$165.18
200-Day MA$150.94
Shares Outstanding0.29B

BDX Computed Insights

FCF$2.67B
FCF Growth Rate1.98%
EPS Growth (CAGR)1.98%
WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

BDX Financial Statements & Data

Becton Dickinson & Company (BDX) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Becton Dickinson & Company's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $21.92B. Gross profit (TTM) is $10.10B. EBITDA is $5.05B. Earnings per share (EPS) is $5.82. The P/E ratio is 25.10. Market capitalization is $44.10B.

Free cash flow (FCF) is $2.67B. FCF growth rate is 1.98%. EPS growth CAGR is 1.98%. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Becton Dickinson & Company's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.